亨廷顿病生物标志物的进展:十年的图书识别分析和全面的审查
Sarah Aqel1, Jamil Ahmad2, Iman Saleh3
1Medical Research Center, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar.
Biology
|February 26, 2025
概括
确定亨廷顿病的可靠生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物标志物研究 生物标志物研究
背景情况:
- 神经退行性疾病 (NDs),包括亨廷顿病 (HD),代表着日益严重的全球健康危机.
- 亨廷顿病是由亨廷丁 (HTT) 基因突变引起的,导致严重的神经元损失和衰弱症状.
- 有效管理HD需要可靠的生物标志物用于早期诊断,进展监测和治疗评估.
研究的目的:
- 进行对亨廷顿病生物标志物研究的10年图书统计分析,以确定趋势和差距.
- 审查HD的新兴生物标志物,重点关注它们在表现前阶段的潜力.
- 强调需要改善患者分层和纵向研究来验证生物标志物的必要性.
主要方法:
- 十年来亨廷顿病生物标志物研究的图书统计分析.
- 对候选湿和成像生物标记物的综合文献综述.
- 评估神经生理学和行为标志物的疾病评估.
主要成果:
- 确定了HD生物标志物发现的关键研究趋势和差距.
- 突出显示了有前途的候选生物标记物,包括神经丝轻链蛋白 (NfL),微RNA和突变HTT.
- 评估神经成像和神经生理学标志物的有用性,以检测结构和功能缺陷.
结论:
- 经过验证的HD生物标志物需要加强患者分层和强大的纵向研究.
- 可靠的生物标志物对于个性化治疗,临床试验的进步和优化疾病管理至关重要.
- 对于早期干预策略来说,专注于预先显现的HD生物标志物是必不可少的.
相关概念视频
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422
Parkinson's Disease: Overview
421
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
421


